Why We Have to Defend Against Screened Cases: Now is the Time for a Change, Part Three

For Part Two of Why We Have to Defend Against Screened Cases: Now is the Time for a Change click here.

Defendants, courts and some commentators choose to turn a blind eye to the mass testing entities' manufacture of claims for various reasons. First, the focus of the defense has generally been on the malignancy cases. While the malignancy cases are individually more expensive for defendants, they are not more expensive when the total number of nonmalignant claims is calculated. At least 65 percent of all asbestos compensation is paid on nonmalignant cases. See Carroll, supra, at …